Filing Flows › Adma Biologics (ADMA) › Q3 2026 › vs Q3 2025
Adma Biologics (ADMA) Q3 2026 vs Q3 2025 (year over year)
Adma Biologics's revenue rose $6.9M (+5%) from $134M in Q3 2025 to $141M in Q3 2026. Gross margin 70.8% against 56.3% (+14.5 pts).
Adma Biologics, Q3 2026: revenue $141M (+5% year over year), operating margin 48.0%, net earnings $49.9M, operating cash flow $17.4M. The chart draws each line against Q3 2025, the increases inside each band.
Margins
| Q3 2026 | Q3 2025 | Change | |
|---|---|---|---|
| Gross margin | 70.8% | 56.3% | +14.5 pts |
| Operating margin | 48.0% | 38.0% | +10.0 pts |
| Net margin | 35.4% | 27.1% | +8.2 pts |
| Free cash flow margin | 10.9% | -0.8% | +11.7 pts |
Every line
| Line | Q3 2026 | Q3 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $141M | $134M | $6.9M | +5% |
| Gross profit | $99.9M | $75.6M | $24.3M | +32% |
| Cost of revenue | $41.2M | $58.6M | −$17.4M | -30% |
| Operating profit | $67.8M | $51.0M | $16.7M | +33% |
| Operating expenses | $32.2M | $24.6M | $7.5M | +31% |
| Pre-tax earnings | $65.6M | $47.5M | $18.1M | +38% |
| Other expense, net | $2.2M | $3.5M | −$1.3M | -38% |
| Research & development | $4.5M | $1.5M | $3.0M | +194% |
| SG&A | $26.6M | $21.8M | $4.8M | +22% |
| Other operating costs | $1.1M | $1.3M | −$195K | -15% |
| Net earnings | $49.9M | $36.4M | $13.5M | +37% |
| Income tax | $15.7M | $11.1M | $4.6M | +42% |
| Depreciation & amortization | $1.7M | $2.0M | −$300K | -15% |
| Share-based compensation | $6.2M | $5.0M | $1.2M | +23% |
| Working capital & other | $40.4M | $30.2M | $10.2M | +34% |
| Operating cash flow | $17.4M | $13.3M | $4.1M | +31% |
| Free cash flow (OCF − capex) | $15.4M | −$1.1M | $16.4M | — |
| Capital expenditures | $2.0M | $14.4M | −$12.4M | -86% |
Questions
How much did Adma Biologics's revenue grow year over year in Q3 2026?
Adma Biologics's revenue rose $6.9M (+5%) from $134M in Q3 2025 to $141M in Q3 2026. Gross margin 70.8% against 56.3% (+14.5 pts).